Adaptive Biotechnologies is charting a massive expansion of its Seattle headquarters following the completion of a recent initial public offering. The company signed a 100,000 square-foot lease, tripling its current footprint in the South Lake Union neighborhood.
Alexandria Real Estate Equities owns the 1165 Eastlake Ave. E location as well as a cluster of life science projects in the area. Adaptive signed a 12-year lease at the location, which is just a few doors down from its current offices at 1551 Eastlake Ave. E, also part of Alexandra’s cluster.
Adaptive plans to move into the new digs in 2021 once the interior is finished.
“We have worked with Alexandria to design a state-of-the-art headquarters that will allow us to expand our lab capacity, R&D footprint, and office space to help realize our goal to translate the genetics of the adaptive immune system into clinical products that we believe will transform medicine and improve patients’ lives,” Adaptive CEO and co-founder Chad Robins said in a statement. “This space will support Adaptive’s strategic growth trajectory, provide our current and future employees with improved space and amenities, and foster our mission-driven culture that drives commitment to each other, our customers, and our patients.”
The company is known for creating technology that can read the human immune system, which it has used to secure deals with Genentech to develop personalized cancer therapies, and with Microsoft to use AI to diagnose multiple diseases from a single blood test.
Adaptive raised raised $300 million in its IPO this past June.
Brothers Chad and Harlan Robins co-founded the company in 2009, leveraging technology that Harlan developed at the Fred Hutchinson Cancer Research Center.
“1165 Eastlake will provide Adaptive with a dynamic headquarters necessary to support the needs of a rapidly growing company that sits at the intersection of life science and technology,” Alexandria executive chairman and founder Joel S. Marcus said in a statement.
Alexandria is also responsible for developing the nearby Lake Union Steam Plant — the former home of biotech ZymoGenetics — for the Fred Hutchinson Cancer Research Center, which will move in next year. The real estate company’s other life science tenants include Celgene, Gilead and the University of Washington.
